Abatacept in the treatment of rheumatoid arthritis

Table 1 Summary of clinical efficacy scores from trials evaluating abatacept

						ACR20 (%)		ACR50 (%)		ACR70 (%)		DAS28 LDAS (%)		DAS28 remission (%)
Trial authors	Study phase	Study cohort	n	Duration	Background therapy	A	P	A	P	A	P	A	P	A	P
Moreland et al. [19]	II	DMARD failure	214	3 months	None	53%	31%
Kremer et al. [20]	II	MTX failure	339	6 months	MTX	60%	35.3%	36.5%	11.8%	16.5%	1.7%
Kremer et al. [21]	II	MTX failure	339	1 year	MTX	62.6%	36.1%	41.7%	20.2%	20.9%	7.6%	49.6%	21.9%	34.8%	10.1%
Kremer et al. [22]	III (AIM)	MTX failure	652	1 year	MTX	73.1%	39.7%	48.3%	18.2%	28.8%	6.1%	42.5%	9.9%	23.8%	1.9%
Genovese et al. [29]	III (ATTAIN)	TNF-α antagonist Failure	391	6 months	MTX, other DMARD	50.4%	19.5%	20.3%	3.8%	10.2%	1.5%	17.1%	3.1%	10%	0.8%
Schiff et al. [28]	III (ATTEST)	MTX failure: abatacept (A) or infliximab (I) active arms	431	6 months	MTX	A: 66.7%	41.8%	A: 40.4%	20%	A: 20.5%	9.1%	A: 20.7%	10.8%	A: 11.3%	2.9%
						I: 59.4%		I: 37%		I: 24.2%		I: 25.6%		I: 12.8%
				1 year	MTX	A: 72.4%		A: 45.5%		A: 26.3%		A: 35.3%		A: 18.7%
						I: 55.8%		I: 36.4%		I: 20.6%		I: 22.4%		I: 12.2%

For abatacept (A), only responses for 10 mg/kg are included. ACR20/50/70, at least 20%/50%/70% improvement in the American College of Rheumatology criteria for rheumatoid arthritis; AIM, Abatacept in Inadequate responders to Methotrexate; ATTAIN, Abatacept Trial in Treatment of Anti-TNF INadequate responders; ATTEST, Abatacept or infliximab versus placebo, a Trial for Tolerability, Efficacy and Safety in Treating RA; DAS28, Disease Activity Score using 28 joint counts; DMARD, disease-modifying antirheumatic drug; LDAS, low disease activity scores; LTE, long-term extension; MTX, methotrexate; P, placebo; TNF, tumor necrosis factor.

ISSN: 1478-6362